Estrogen Deficiency and the Origin of Obesity during Menopause
Open accessThe DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index; 16 of the 142 sources its claims cite were checked for support.
Abstract
Sex hormones strongly influence body fat distribution and adipocyte differentiation. Estrogens and testosterone differentially affect adipocyte physiology, but the importance of estrogens in the development of metabolic diseases during menopause is disputed. Estrogens and estrogen receptors regulate various aspects of glucose and lipid metabolism. Disturbances of this metabolic signal lead to the development of metabolic syndrome and a higher cardiovascular risk in women. The absence of estrogens is a clue factor in the onset of cardiovascular disease during the menopausal period, which is characterized by lipid profile variations and predominant abdominal fat accumulation. However, influence of the absence of these hormones and its relationship to higher obesity in women during menopause are not clear. This systematic review discusses of the role of estrogens and estrogen receptors in adipocyte differentiation, and its control by the central nervous systemn and the possible role of estrogen-like compounds and endocrine disruptors chemicals are discussed. Finally, the interaction between the decrease in estrogen secretion and the prevalence of obesity in menopausal women is examined. We will consider if the absence of estrogens have a significant effect of obesity in menopausal women.
Overview
CoChat Summary
TL;DR
This systematic review examines whether estrogen deficiency contributes to obesity during menopause, covering estrogen receptors, adipocyte biology, central appetite regulation, adipokines, endocrine disruptors, and hormone therapy. It concludes that estrogen loss is linked to abdominal fat accumulation and metabolic risk, but causality and optimal hormone therapy remain unclear.
Key findings
- Estrogen deficiency after menopause is associated with loss of subcutaneous fat and an increase in abdominal fat; obesity prevalence in American women reaches 65% between ages 40–59 and 73.8% over age 60, and menopausal women are three times more likely to develop obesity and metabolic syndrome abnormalities than premenopausal women.
- Estrogen receptors, especially ERα, mediate metabolic effects: female and male mice lacking ERα have central obesity, severe insulin resistance, and diabetes; E2 administered to ovariectomized mice on a high-fat diet improved glucose tolerance and insulin sensitivity in wild-type but not ERα−/− mice.
- Estrogens influence appetite and energy regulation: they inhibit orexigenic NPY and MCH effects, deletion of ER in POMC neurons in mice leads to hyperphagia without directly influencing energy expenditure or adipose tissue distribution, and ovariectomized rats regain normal weight after estrogen replacement.
- Hormone therapy findings are mixed: a meta-analysis of over 100 randomized trials in menopausal women concluded that oral and transdermal estrogen, with or without progestin, increases lean body mass, reduces abdominal fat, improves insulin resistance, decreases LDL/HDL cholesterol ratio, and decreases blood pressure in women without diabetes; WHI DXA at six-year follow-up showed decreased loss of body fat mass with hormonal therapy in the first three years but not after six years.
Methods
- The study design was a review of existing published original papers and reviews, conducted in accordance with the PRISMA statement.
- PubMed publications until Nov 30, 2013, were taken into account.
- No primary data collection or quantitative meta-analysis is reported; the synthesis is narrative across animal and human studies.
Limitations
- The paper states that the influence of estrogen absence and its relationship to higher obesity in menopausal women are not clear, that reasons for increasing obesity in menopausal women are not clear, and that triggers for obesity require further investigation; it also states that further studies are required to clarify endocrine disruptor involvement and that stringent studies in different locations are essential.
- The paper states that hormone therapy during menopause will always be a mixed picture of benefits and risks, requiring individual assessment of needs and potential risks.
- Evident from the text: as a review, it does not report a formal quantitative synthesis, risk-of-bias assessment, or detailed inclusion/exclusion criteria, and it draws on heterogeneous animal models and human studies, limiting causal conclusions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
8 Valid · 2 Not valid · 67 Not checked · 4 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Estrogen increases leptin sensitivity by controlling the expression of leptin-specific receptors [130–132].”
§ Estrogen Deficiency and the Origin of Obesity during Menopause > 6. Estrogen and Adipokine Secretion
What the sources say
- Not checked yetcites [130] Ladyman SR Grattan DR Suppression of leptin receptor mRNA and leptin responsiveness in the ventromedial nucleus of the hypothalamus during pregnancy in the rat Endocrinology 2005 146 9 3868 3874 2-s2.0-23844457685 15905318 source
- Disputedcites [131] Clegg DJ Brown LM Woods SC Benoit SC Gonadal hormones determine sensitivity to central leptin and insulin Diabetes 2006 55 978 987 16567519 sourceExperimental — accuracy not yet measured
The Discussion reports that estradiol increases central leptin sensitivity, but it does not establish receptor-expression control as the cause. It says the observed sensitivity differences must occur downstream of leptin-receptor (OB-Rb) gene expression, contrary to the mechanism stated in the claim. Page numbers are unavailable in our copy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [132] Lobo RA Metabolic syndrome after menopause and the role of hormones Maturitas 2008 60 1 10 18 2-s2.0-45649083873 18407440 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Disturbances of this metabolic signal lead to the development of metabolic syndrome and a higher cardiovascular risk in women.”
- Also stated in: § 1. Introduction · plain
“Estrogens deficiency enhances metabolic dysfunction predisposing to DM type 2, the metabolic syndrome, and cardiovascular diseases [31, 32].”
§ Estrogen Deficiency and the Origin of Obesity during Menopause > Abstract
What the sources say
- Not checked yetcites [31] Carr MC The emergence of the metabolic syndrome with menopause Journal of Clinical Endocrinology and Metabolism 2003 88 6 2404 2411 2-s2.0-0038645816 12788835 source
- Partly supportedcites [32] Mauvais-Jarvis F Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity Trends in Endocrinology and Metabolism 2011 22 1 24 33 2-s2.0-78650521925 21109497 PMC3011051 sourceExperimental — accuracy not yet measured
The 'Contribution of sex hormones to metabolic diseases' section states that postmenopausal women live in estrogen deficiency 'which predisposes to the metabolic syndrome and T2D', and the 'ERs improve insulin sensitivity' section reports that E2 deficiency/resistance provokes insulin resistance and glucose intolerance — so the T2D/metabolic-syndrome and metabolic-dysfunction parts of the claim are in our copy. However, no passage in our copy (searched: cardiovascular disease, atherosclerosis, coronary risk, menopause and cardiovascular events) links estrogen deficiency to cardiovascular diseases; the review's stated scope is obesity, T2D and metabolic syndrome via ERs/AR. The cardiovascular-disease extension attributed to this source is therefore not supported by it. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“OVX rats, which are induced to exhibit obesity, regain normal weight after estrogen replacement [36, 110].”
§ Estrogen Deficiency and the Origin of Obesity during Menopause > 5. Estrogen and Energy Regulation
What the sources say
- Partly supportedcites [36] Heine PA Taylor JA Iwamoto GA Lubahn DB Cooke PS Increased adipose tissue in male and female estrogen receptor-α knockout mice Proceedings of the National Academy of Sciences of the United States of America 2000 97 23 12729 12734 2-s2.0-0033749264 11070086 PMC18832 sourceExperimental — accuracy not yet measured
The Discussion (page not available) says ovariectomized rats develop increased fat and that white adipose tissue decreases after estrogen replacement. It does not say that estrogen replacement returns the rats to normal body weight; fat deposition and body weight are not interchangeable. (LLM, conf=0.85)
- Not checked yetcites [110] Antonson P Omoto Y Humire P Gustafsson JA Generation of ERalpha-floxed and knockout mice using the Cre/LoxP system Biochemical and Biophysical Research Communications 2012 424 710 716 22800760 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Adiponectin plasma level is indirectly and negatively correlated with E2 plasma levels.”
§ Estrogen Deficiency and the Origin of Obesity during Menopause > 6. Estrogen and Adipokine Secretion
What the sources say
- Not checked yetcites [133] Combs TP Pajvani UB Berg AH A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity Endocrinology 2004 145 1 367 383 2-s2.0-9144263120 14576179 source
- Partly supportedcites [134] Combs TP Berg AH Rajala MW Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin Diabetes 2003 52 2 268 276 2-s2.0-0037317488 12540596 sourceExperimental — accuracy not yet measured
The Discussion (p. 5) describes an inverse relationship between estrogen and plasma adiponectin (Acrp30) in adult mice, but says their relationship during puberty differs. The Results (pp. 3–4) show that E2 exposure lowers Acrp30; they do not establish a general correlation between measured plasma E2 and adiponectin levels. The paper also finds evidence of direct E2 action on adipocytes, so an indirect mechanism is not established. (LLM, conf=0.84)
- Not checked yetcites [135] Rose DP Komninou D Stephenson GD Obesity, adipocytokines, and insulin resistance in breast cancer Obesity Reviews 2004 5 3 153 165 2-s2.0-3242883351 15245384 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, Genistein reverses the truncal fat accumulation in postmenopausal women and ovariectomized rodent models [144, 145].”
§ Estrogen Deficiency and the Origin of Obesity during Menopause > 7. Estrogen-Like Compounds and Endocrine Disruptors
What the sources say
- Partly supportedcites [144] Wu J Oka J Tabata I Effects of isoflavone and exercise on BMD and fat mass in postmenopausal Japanese women: a 1-year randomized placebo-controlled trial Journal of Bone and Mineral Research 2006 21 5 780 789 2-s2.0-33646250884 16734394 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable in our copy) reports that isoflavone intake significantly reduced trunk fat mass in postmenopausal Japanese women. But the Intervention section describes a mixture of isoflavones, not genistein alone. The paper also refers to earlier work on fat gain in estrogen-deficient animals, but does not establish that genistein reversed truncal fat accumulation in ovariectomized rodents. (LLM, conf=0.89)
- Partly supportedcites [145] Kim H-K Nelson-Dooley C Della-Fera MA Genistein decreases food intake, body weight, and fat pad weight and causes adipose tissue apoptosis in ovariectomized female mice Journal of Nutrition 2006 136 2 409 414 2-s2.0-32444442906 16424120 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that genistein decreased body weight and body fat in older ovariectomized mice. It also says genistein intake was associated with lower waist circumference and body fat in postmenopausal women. Those passages support effects on adiposity, but do not establish that genistein reverses truncal fat accumulation in either group; the evidence for women is described as an association. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
25 more claims · 1 with their cited sources checked
Create a free account to see all 81 claims and to verify the 125 references still open.
- It may state two separate claims as one. 40
- Probably not a substantial claim. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This protective effect appears to diminish in postmenopausal women, where a decrease in circulating E2 by the gonads leads to a deficiency, which has been associated with increased VAT deposition (168).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [168]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Estrogen Deficiency and the Origin of Obesity during Menopause > 2. Methods
“We conducted this review of SSBs and health outcomes in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement (PRISMA) [35].”
§ Estrogen Deficiency and the Origin of Obesity during Menopause > Abstract
“This systematic review discusses of the role of estrogens and estrogen receptors in adipocyte differentiation, and its control by the central nervous systemn and the possible role of estrogen-like compounds and endocrine disruptors chemicals are discussed.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Estrogen Deficiency and the Origin of Obesity during Menopause > 7. Estrogen-Like Compounds and Endocrine Disruptors
“However, tibolona combined with 17-β-estradiol and norethindrone acetate for 2 years does not significantly decrease fat mass [142].”
§ Estrogen Deficiency and the Origin of Obesity during Menopause > References
“142. Boyanov MA Shinkov AD Effects of tibolone on body composition in postmenopausal women: a 1-year follow up study Maturitas 2005 51 4 363 369 2-s2.0-22544475568 16039409 10.1016/j.maturitas.2004.09.003”
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement
Diamanti-Kandarakis, E., Bourguignon, J.-P., Giudice, L. C., Hauser, R., Prins, G. S., Soto, A. M., Zoeller, R. T., & Gore, A. C. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0002 · Cited by 4,585
Mechanisms of fatty acid-induced inhibition of glucose uptake.
Boden, G., Chen, X., Ruiz, J., White, J. V., & Rossetti, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117252 · Cited by 3,705
A role for ghrelin in the central regulation of feeding
Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., & Matsukura, S. (2001) · Nature · doi:10.1038/35051587 · Cited by 3,443 · cited 1×
“Thepotential therapeutic relevance of estrogen physiology, estrogen receptors, and the estrogen pathway will be discussed in this manuscript.”
BackgroundEuropean Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Research works printed but not linked: 12
- 2012, Obesity, 20, 2183
- 1988, Acta Medica Scandinavica, 223, 121
- 2012, PLOS Genetics, 8
- 2002, Journal of Nutrition, Health and Aging, 6, 123
- 2001, American Journal of Physiology, 280, E496
- 1999, American Journal of Physiology, 276, E317
- 2001, Cell, 104, 719
- 2012, American Journal of Physiology, 303, E445
- 2013, American Journal of Physiology, 304, E1167
- 2013, International Journal of Obesity
- 2013, Journal of Clinical Endocrinology and Metabolism
- 1987, Neuroscience Letters, 84, 197
Cited by
A review on plant-based proteins from soybean: Health benefits and soy product development
Qin, P., Wang, T., & Luo, Y. (2022) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2021.100265 · Cited by 578
The regulation of adipose tissue health by estrogens
Steiner, B. M., & Berry, D. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.889923 · Cited by 171
Compositional and functional features of the female premenopausal and postmenopausal gut microbiota
Zhao, H., Chen, J., Li, X., Sun, Q., Qin, P., & Wang, Q. (2019) · FEBS Letters · doi:10.1002/1873-3468.13527 · Cited by 138
Unraveling female reproductive senescence to enhance healthy longevity
Dong, L., Teh, D. B. L., Kennedy, B. K., & Huang, Z. (2023) · Cell Research · doi:10.1038/s41422-022-00718-7 · Cited by 101
“Importantly, several agerelated chronic diseases are disproportionately affected by the onset of menopause.(11,12) For instance, there are heightened risks of neurocognitive decline,(13) cardiovascular diseases (CVDs),(14)”
BackgroundMechanisms IN endocrinology: metabolic syndrome through the female life cycle
Vryonidou, A., Paschou, S. A., Muscogiuri, G., Orio, F., & Goulis, D. G. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0275 · Cited by 88
Metadata
- Authors
- Lizcano, F., & Guzmán, G.
- Affiliations
- Universidad de La Sabana (CO)
- Corresponding author
- Lizcano, Fernando
- Venue
- BioMed Research International
- Publisher
- Hindawi Limited
- Published
- 2014
- Volume
- 2014
- Pages
- 1-11
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC3964739
- OpenAlex
- W1985061586
- Cited by
- 586
- References
- 172
- Citations by year
- 2026: 38 · 2025: 65 · 2024: 64 · 2023: 59 · 2022: 67 · 2021: 65 · 2020: 64 · 2019: 47 · 2018: 42 · 2017: 24 · 2016: 27 · 2015: 19 · 2014: 5
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Intellectum (Universidad de La Sabana) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- estrogen deficiency, menopause, obesity, estrogen receptor, adipogenesis, body fat distribution, metabolic syndrome, cardiovascular risk, lipid profile, abdominal fat, endocrine disruptors, estrogenic compounds, sex hormones
- MeSH terms
- Central Nervous System, Estradiol, Estrogens, Female, Humans, Menopause, Middle Aged, Obesity, Receptors, Estrogen, Overweight, Lipid Metabolism, Adipokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.